Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Annexon Biosciences ( (ANNX) ).
On January 12, 2026, Annexon outlined 2026 as a pivotal year, detailing registrational milestones across its lead assets and emphasizing a balance sheet that funds operations into late 2027. The company highlighted vonaprument, a neuroprotective therapy in the global Phase 3 ARCHER II trial for dry age-related macular degeneration with geographic atrophy, with enrollment completed ahead of schedule and topline data expected in the second half of 2026, supported by a defined U.S. and European registration path and earlier clinical evidence of significant protection of photoreceptors and vision. Annexon also reported that tanruprubart, positioned as a fast-acting treatment for Guillain-Barré syndrome, has an EU marketing application under review supported by placebo-controlled and real-world data, while an ongoing FORWARD study in the U.S. and Europe is intended to underpin a planned 2026 biologics license application. In parallel, the company is advancing ANX1502, a first-in-kind oral C1 inhibitor for autoimmune conditions, with a proof-of-concept trial in cold agglutinin disease under way assessing pharmacokinetics, pharmacodynamics and complement inhibition, and an update on this program anticipated in 2026, underscoring Annexon’s broader push to expand its complement-targeting immunotherapy platform.
The most recent analyst rating on (ANNX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Annexon Biosciences stock, see the ANNX Stock Forecast page.
Spark’s Take on ANNX Stock
According to Spark, TipRanks’ AI Analyst, ANNX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn). Offsetting this are strong technical momentum signals and a financing event that improves liquidity, while valuation remains constrained by ongoing losses and no dividend support.
To see Spark’s full report on ANNX stock, click here.
More about Annexon Biosciences
Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company developing a next-generation platform of targeted immunotherapies for serious neuroinflammatory diseases affecting nearly 10 million people worldwide. Its science focuses on inhibiting C1q, the initiating molecule of the classical complement pathway, to halt complement-driven neuroinflammation at its source and provide meaningful functional benefit across a range of conditions.
Average Trading Volume: 2,752,471
Technical Sentiment Signal: Buy
Current Market Cap: $765.6M
For a thorough assessment of ANNX stock, go to TipRanks’ Stock Analysis page.